Cargando…

Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People

Long-term care facility (LTCF) older residents display physiological alterations of cellular and humoral immunity that affect vaccine responses. Preliminary reports suggested a low early postvaccination antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim o...

Descripción completa

Detalles Bibliográficos
Autores principales: Demaret, Julie, Corroyer-Simovic, Bénédicte, Alidjinou, Enagnon Kazali, Goffard, Anne, Trauet, Jacques, Miczek, Sophie, Vuotto, Fanny, Dendooven, Arnaud, Huvent-Grelle, Dominique, Podvin, Juliette, Dreuil, Daniel, Faure, Karine, Deplanque, Dominique, Bocket, Laurence, Duhamel, Alain, Labreuche, Julien, Sobaszek, Annie, Hisbergues, Michael, Puisieux, Francois, Labalette, Myriam, Lefèvre, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637126/
https://www.ncbi.nlm.nih.gov/pubmed/34868051
http://dx.doi.org/10.3389/fimmu.2021.778679
_version_ 1784608679482359808
author Demaret, Julie
Corroyer-Simovic, Bénédicte
Alidjinou, Enagnon Kazali
Goffard, Anne
Trauet, Jacques
Miczek, Sophie
Vuotto, Fanny
Dendooven, Arnaud
Huvent-Grelle, Dominique
Podvin, Juliette
Dreuil, Daniel
Faure, Karine
Deplanque, Dominique
Bocket, Laurence
Duhamel, Alain
Labreuche, Julien
Sobaszek, Annie
Hisbergues, Michael
Puisieux, Francois
Labalette, Myriam
Lefèvre, Guillaume
author_facet Demaret, Julie
Corroyer-Simovic, Bénédicte
Alidjinou, Enagnon Kazali
Goffard, Anne
Trauet, Jacques
Miczek, Sophie
Vuotto, Fanny
Dendooven, Arnaud
Huvent-Grelle, Dominique
Podvin, Juliette
Dreuil, Daniel
Faure, Karine
Deplanque, Dominique
Bocket, Laurence
Duhamel, Alain
Labreuche, Julien
Sobaszek, Annie
Hisbergues, Michael
Puisieux, Francois
Labalette, Myriam
Lefèvre, Guillaume
author_sort Demaret, Julie
collection PubMed
description Long-term care facility (LTCF) older residents display physiological alterations of cellular and humoral immunity that affect vaccine responses. Preliminary reports suggested a low early postvaccination antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim of this study was to focus on the specific T-cell response. We quantified S1-specific IgG, neutralizing antibody titers, total specific IFNγ-secreting T cells by ELISpot, and functionality of CD4(+)- and CD8(+)-specific T cells by flow cytometry, after two doses of the BNT162b2 vaccine in younger and older people, with and without previous COVID-19 infection (hereafter referred to as COVID-19-recovered and COVID-19-naive subjects, respectively). Frailty, nutritional, and immunosenescence parameters were collected at baseline in COVID-19-naive older people. We analyzed the immune response in 129 young adults (median age 44.0 years) and 105 older residents living in a LCTF (median age 86.5 years), 3 months after the first injection. Humoral and cellular memory responses were dramatically impaired in the COVID-19-naive older (n = 54) compared with the COVID-19-naive younger adults (n = 121). Notably, older participants’ neutralizing antibodies were 10 times lower than the younger’s antibody titers (p < 0.0001) and LCTF residents also had an impaired functional T-cell response: the frequencies of IFNγ(+) and IFNγ(+)IL-2(+)TNFα(+) cells among specific CD4(+) T cells, and the frequency of specific CD8(+) T cells were lower in COVID-19-naive older participants than in COVID-19-naive young adults (p < 0.0001 and p = 0.0018, respectively). However, COVID-19-recovered older participants (n = 51) had greater antibody and T-cell responses, including IFNγ(+) and IFNγ(+)IL-2(+)TNFα(+)-specific CD4(+) T cells (p < 0.0001), as well as TNFα(+)-specific CD8(+) T cells (p < 0.001), than COVID-19-naive older adults. We also observed that “inflammageing” and particularly high plasma levels of TNFα was associated to poor antibody response in the older participants. In conclusion, our results show that the COVID-19-naive older people had low counts and impaired specific CD4(+) and CD8(+) T cells, in addition to impaired antibody response, and that specific studies are warranted to assess the efficiency of SARS-CoV-2 mRNA-based vaccines, as in other immunocompromised subjects. Our study also shows that, despite their physiological alterations of immunity, vaccination is highly efficient in boosting the prior natural memory response in COVID-19-recovered older people.
format Online
Article
Text
id pubmed-8637126
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86371262021-12-03 Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People Demaret, Julie Corroyer-Simovic, Bénédicte Alidjinou, Enagnon Kazali Goffard, Anne Trauet, Jacques Miczek, Sophie Vuotto, Fanny Dendooven, Arnaud Huvent-Grelle, Dominique Podvin, Juliette Dreuil, Daniel Faure, Karine Deplanque, Dominique Bocket, Laurence Duhamel, Alain Labreuche, Julien Sobaszek, Annie Hisbergues, Michael Puisieux, Francois Labalette, Myriam Lefèvre, Guillaume Front Immunol Immunology Long-term care facility (LTCF) older residents display physiological alterations of cellular and humoral immunity that affect vaccine responses. Preliminary reports suggested a low early postvaccination antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim of this study was to focus on the specific T-cell response. We quantified S1-specific IgG, neutralizing antibody titers, total specific IFNγ-secreting T cells by ELISpot, and functionality of CD4(+)- and CD8(+)-specific T cells by flow cytometry, after two doses of the BNT162b2 vaccine in younger and older people, with and without previous COVID-19 infection (hereafter referred to as COVID-19-recovered and COVID-19-naive subjects, respectively). Frailty, nutritional, and immunosenescence parameters were collected at baseline in COVID-19-naive older people. We analyzed the immune response in 129 young adults (median age 44.0 years) and 105 older residents living in a LCTF (median age 86.5 years), 3 months after the first injection. Humoral and cellular memory responses were dramatically impaired in the COVID-19-naive older (n = 54) compared with the COVID-19-naive younger adults (n = 121). Notably, older participants’ neutralizing antibodies were 10 times lower than the younger’s antibody titers (p < 0.0001) and LCTF residents also had an impaired functional T-cell response: the frequencies of IFNγ(+) and IFNγ(+)IL-2(+)TNFα(+) cells among specific CD4(+) T cells, and the frequency of specific CD8(+) T cells were lower in COVID-19-naive older participants than in COVID-19-naive young adults (p < 0.0001 and p = 0.0018, respectively). However, COVID-19-recovered older participants (n = 51) had greater antibody and T-cell responses, including IFNγ(+) and IFNγ(+)IL-2(+)TNFα(+)-specific CD4(+) T cells (p < 0.0001), as well as TNFα(+)-specific CD8(+) T cells (p < 0.001), than COVID-19-naive older adults. We also observed that “inflammageing” and particularly high plasma levels of TNFα was associated to poor antibody response in the older participants. In conclusion, our results show that the COVID-19-naive older people had low counts and impaired specific CD4(+) and CD8(+) T cells, in addition to impaired antibody response, and that specific studies are warranted to assess the efficiency of SARS-CoV-2 mRNA-based vaccines, as in other immunocompromised subjects. Our study also shows that, despite their physiological alterations of immunity, vaccination is highly efficient in boosting the prior natural memory response in COVID-19-recovered older people. Frontiers Media S.A. 2021-11-16 /pmc/articles/PMC8637126/ /pubmed/34868051 http://dx.doi.org/10.3389/fimmu.2021.778679 Text en Copyright © 2021 Demaret, Corroyer-Simovic, Alidjinou, Goffard, Trauet, Miczek, Vuotto, Dendooven, Huvent-Grelle, Podvin, Dreuil, Faure, Deplanque, Bocket, Duhamel, Labreuche, Sobaszek, Hisbergues, Puisieux, Labalette and Lefèvre https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Demaret, Julie
Corroyer-Simovic, Bénédicte
Alidjinou, Enagnon Kazali
Goffard, Anne
Trauet, Jacques
Miczek, Sophie
Vuotto, Fanny
Dendooven, Arnaud
Huvent-Grelle, Dominique
Podvin, Juliette
Dreuil, Daniel
Faure, Karine
Deplanque, Dominique
Bocket, Laurence
Duhamel, Alain
Labreuche, Julien
Sobaszek, Annie
Hisbergues, Michael
Puisieux, Francois
Labalette, Myriam
Lefèvre, Guillaume
Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
title Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
title_full Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
title_fullStr Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
title_full_unstemmed Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
title_short Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
title_sort impaired functional t-cell response to sars-cov-2 after two doses of bnt162b2 mrna vaccine in older people
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637126/
https://www.ncbi.nlm.nih.gov/pubmed/34868051
http://dx.doi.org/10.3389/fimmu.2021.778679
work_keys_str_mv AT demaretjulie impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT corroyersimovicbenedicte impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT alidjinouenagnonkazali impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT goffardanne impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT trauetjacques impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT miczeksophie impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT vuottofanny impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT dendoovenarnaud impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT huventgrelledominique impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT podvinjuliette impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT dreuildaniel impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT faurekarine impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT deplanquedominique impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT bocketlaurence impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT duhamelalain impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT labreuchejulien impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT sobaszekannie impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT hisberguesmichael impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT puisieuxfrancois impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT labalettemyriam impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople
AT lefevreguillaume impairedfunctionaltcellresponsetosarscov2aftertwodosesofbnt162b2mrnavaccineinolderpeople